Overview

The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

Status:
Active, not recruiting

Trial end date:
2021-10-30

Target enrollment:

Participant gender:

Summary

Cilostazol is a PDE 3 inhibitor, which showed as decrease in HAM-D scores in post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and through promotion of neurogenesis. These beneficial effects on post-stroke depression may be involved in activation of CREB/BDNF signaling.The aim of the current study is to evaluate the potential adjunct antidepressant effect of cilostazol in adult patients with MDD. Furthermore, we will assess the relationship between HAM-D score and BDNF as well as their role as a therapeutic targets of MDD.

Phase:

N/A

Details

Lead Sponsor:

Sadat City University

Treatments:

Antidepressive Agents
Cilostazol
Citalopram
Dexetimide
Phosphodiesterase 3 Inhibitors